Van der Molen T, Pieters W, Bellamy D, Taylor R
Department of General Practice, University Hospital Groningen, The Netherlands.
Respir Med. 2002 Aug;96 Suppl C:S17-21. doi: 10.1016/s0954-6111(02)80030-0.
The success of treatments for chronic obstructive pulmonary disease (COPD) is evaluated by measuring the impact on a range of health outcomes. However, outcome measures differ in their relative importance to the various stakeholder groups. Patients are most interested in the impact on quality of life and on mortality, while physicians also value information about the effect of treatments on lung function and disease progression. In contrast to patients and physicians, healthcare payers take a population perspective, and need to balance the health gains achieved and the costs of treatment. If the management of COPD is to be improved, it is important, first, to understand the outcomes of importance to each relevant stakeholder group, and then second, to refocus the measures in terms that all stakeholders can value.
慢性阻塞性肺疾病(COPD)治疗的成功与否是通过衡量其对一系列健康结果的影响来评估的。然而,结果指标对不同利益相关者群体的相对重要性各不相同。患者最关心对生活质量和死亡率的影响,而医生也重视有关治疗对肺功能和疾病进展影响的信息。与患者和医生不同,医疗保健支付方从人群角度出发,需要平衡所取得的健康收益和治疗成本。如果要改善慢性阻塞性肺疾病的管理,首先重要的是了解对每个相关利益相关者群体重要的结果,其次是以所有利益相关者都能重视的方式重新聚焦这些指标。